Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 10/20 | 0.60 |
| ▸ | APP | P05067 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | MGLL | Q99685 | 1/20 | 0.47 |
| ▸ | ACHE | P22303 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 2/20 | 0.41 |
| ▸ | NOS1 | P29475 | 1/20 | 0.41 |
| ▸ | NOS2 | P35228 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31530153 | 1.00 | MAOB (0.60) | MAOBAPPTP53CYP3A4MGLL | |
| SCHEMBL25920596 | 0.89 | MAOB (0.60) | MAOBAPPTP53CYP3A4MGLL | |
| SCHEMBL31530361 | 0.89 | MAOB (0.60) | MAOBAPPTP53CYP3A4MGLL | |
| SCHEMBL31408860 | 0.84 | CA1 (0.50) | MAOBAPPTP53CYP3A4 | |
| SCHEMBL32665338 | 0.80 | IDO1 (0.57) | CYP3A4 | |
| Hydrochloric Acid SCHEMBL32665385 | 0.79 | IDO1 (0.58) | CYP3A4 | |
| SCHEMBL30633287 | 0.77 | MAOB (0.73) | MAOBAPPMAOANR4A2 | |
| SCHEMBL811194 | 0.77 | MAOB (0.73) | MAOBAPPMAOANR4A2 | |
| SCHEMBL810700 | 0.77 | MAOB (0.70) | MAOBAPPTP53CYP3A4 | |
| SCHEMBL4639569 | 0.77 | MAOB (0.64) | MAOBAPPTP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI (US) | 2023-08-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230242496-A1 | SOX11 INHIBITORS FOR TREATING MANTLE CELL LYMPHOMA | BCL6, SOX18, BCL3 | MAOB 4046/4885APP 4723/4885TP53 205/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.